C. Ruel

发表

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors

D. Gandara, H. Lenz, A. El-Khoueiry, 2014, British Journal of Cancer.

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

P. Kaesberg, P. Frankel, S. Forman, 2020, Leukemia & lymphoma.

Human Papillomavirus Infection as a Prognostic Factor in Oropharyngeal Squamous Cell Carcinoma Patients Treated in a Prospective Phase II Clinical Trial

S. Wilczynski, S. Shibata, Keqiang Zhang, 2013 .

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib

P. Frankel, T. Synold, P. Twardowski, 2008, Cancer investigation.

p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

L. Leong, S. Wilczynski, P. Frankel, 2018, Clinical Cancer Research.

A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction

M. Fakih, P. Frankel, J. Gong, 2019, The oncologist.

Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.

C. Lau, M. Kortylewski, P. Frankel, 2015, The Journal of urology.

Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement

P. Frankel, S. Okuno, W. Chow, 2022, Journal of oncology.

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

J. Doroshow, D. Gandara, H. Lenz, 2015, Cancer Chemotherapy and Pharmacology.

Assessment of relative tumor burden in patients with clinical T1c prostate cancer treated with either external beam or radical prostatectomy.

G. Bellman, A. Kagan, C. Ruel, 1999, American journal of clinical oncology.

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

P. Frankel, S. Forman, J. Tuscano, 2014 .

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

P. Frankel, J. Tuscano, C. Costello, 2019, Blood.

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

J. Waisman, J. S. Lee, P. Frankel, 2022, Cancers.

A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid‐derived suppressor cells for Agaricus bisporus–induced prostate‐specific antigen responses

N. Kanaya, Shiuan Chen, P. Frankel, 2015, Cancer.

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine

J. Doroshow, H. Lenz, A. El-Khoueiry, 2015, Cancer Chemotherapy and Pharmacology.

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.

C. Presant, J. S. Lee, P. Frankel, 2021, European journal of cancer.

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.

J. Waisman, J. S. Lee, P. Frankel, 2020, The oncologist.

Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma

J. Doroshow, D. Gandara, P. Gumerlock, 2004, Cancer.

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

D. Gandara, S. Ramalingam, P. Frankel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

J. Kirkwood, A. Chen, D. Gandara, 2011, Clinical Cancer Research.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

A. Chen, D. Gandara, M. Goetz, 2017, Clinical Cancer Research.

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma

P. Frankel, M. Milhem, S. Okuno, 2019, Cancer.

NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

J. Kirkwood, A. Chen, H. Tawbi, 2018, Cancer.

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

S. Kane, L. Leong, C. Russell, 2012, Breast Cancer Research and Treatment.

A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.

S. Highlander, J. Waisman, J. S. Lee, 2020, The oncologist.

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

K. Foon, P. Frankel, J. Tuscano, 2014, Leukemia & lymphoma.

Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients.

Roger R. Wang, G. Srinivasan, P. Frankel, 2019, JCI insight.

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Y. Yen, L. Leong, P. Frankel, 2019, Cancer treatment and research communications.

Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells

M. Stastny, Christine E. Brown, M. Jensen, 2007, Journal of pediatric hematology/oncology.

Resident memory CD 8 + T cells within cancer islands mediate survival in breast cancer patients

Roger R. Wang, G. Srinivasan, P. Frankel, 2019 .

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

D. Gandara, E. Heath, W. Stadler, 2010, Urology.

Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial

A. Amini, L. Leong, P. Frankel, 2022, Cancers.

Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin.

J. Kirkwood, P. Frankel, K. Margolin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study

D. Gandara, H. Lenz, R. Bold, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.

J. Waisman, P. Frankel, J. Mortimer, 2021 .

Assessment of low prostate weight as a determinant of a higher positive margin rate after laparoscopic radical prostatectomy: a prospective pathologic study of 1,500 cases

P. Chu, R. Nelson, L. Weiss, 2009, Surgical Endoscopy.

Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial.

D. Gandara, E. Heath, W. Stadler, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.

Y. Yen, Xiyong Liu, B. Paz, 2009, Anticancer research.

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer

J. Waisman, P. Frankel, G. Somlo, 2022, Cancer.

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

A. Krishnan, P. Frankel, G. Somlo, 2006, Bone Marrow Transplantation.

Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA

M. Fakih, P. Frankel, L. Rodriguez-Rodriguez, 2023, Annals of Surgical Oncology.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

J. Waisman, J. S. Lee, P. Frankel, 2023, Cancer Immunology, Immunotherapy.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

D. Gandara, E. Heath, W. Stadler, 2010, Urology.

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

J. Waisman, P. Frankel, L. Vora, 2023, The oncologist.